000132793 001__ 132793
000132793 005__ 20240229105032.0
000132793 0247_ $$2doi$$a10.1186/s13058-018-0955-5
000132793 0247_ $$2pmid$$apmid:29665866
000132793 0247_ $$2pmc$$apmc:PMC5905156
000132793 0247_ $$2ISSN$$a1465-5411
000132793 0247_ $$2ISSN$$a1465-542X
000132793 0247_ $$2altmetric$$aaltmetric:38220183
000132793 037__ $$aDKFZ-2018-00437
000132793 041__ $$aeng
000132793 082__ $$a610
000132793 1001_ $$aCampa, Daniele$$b0
000132793 245__ $$aMitochondrial DNA copy number variation, leukocyte telomere length, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
000132793 260__ $$aLondon$$bBioMed Central$$c2018
000132793 3367_ $$2DRIVER$$aarticle
000132793 3367_ $$2DataCite$$aOutput Types/Journal article
000132793 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525781719_9511
000132793 3367_ $$2BibTeX$$aARTICLE
000132793 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132793 3367_ $$00$$2EndNote$$aJournal Article
000132793 520__ $$aLeukocyte telomere length (LTL) and mitochondrial genome (mtDNA) copy number and deletions have been proposed as risk markers for various cancer types, including breast cancer (BC).To gain a more comprehensive picture on how these markers can modulate BC risk, alone or in conjunction, we performed simultaneous measurements of LTL and mtDNA copy number in up to 570 BC cases and 538 controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. As a first step, we measured LTL and mtDNA copy number in 96 individuals for which a blood sample had been collected twice with an interval of 15 years.According to the intraclass correlation (ICC), we found very good stability over the time period for both measurements, with ICCs of 0.63 for LTL and 0.60 for mtDNA copy number. In the analysis of the entire study sample, we observed that longer LTL was strongly associated with increased risk of BC (OR 2.71, 95% CI 1.58-4.65, p = 3.07 × 10- 4 for highest vs. lowest quartile; OR 3.20, 95% CI 1.57-6.55, p = 1.41 × 10- 3 as a continuous variable). We did not find any association between mtDNA copy number and BC risk; however, when considering only the functional copies, we observed an increased risk of developing estrogen receptor-positive BC (OR 2.47, 95% CI 1.05-5.80, p = 0.04 for highest vs. lowest quartile).We observed a very good correlation between the markers over a period of 15 years. We confirm a role of LTL in BC carcinogenesis and suggest an effect of mtDNA copy number on BC risk.
000132793 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132793 588__ $$aDataset connected to CrossRef, PubMed,
000132793 7001_ $$0P:(DE-He78)9c1a5b028ca0ab2ef3468a9266f81f63$$aBarrdahl, Myrto$$b1$$udkfz
000132793 7001_ $$aSantoro, Aurelia$$b2
000132793 7001_ $$aSeveri, Gianluca$$b3
000132793 7001_ $$aBaglietto, Laura$$b4
000132793 7001_ $$aOmichessan, Hanane$$b5
000132793 7001_ $$aTumino, Rosario$$b6
000132793 7001_ $$aBueno-de-Mesquita, H B As$$b7
000132793 7001_ $$aPeeters, Petra H$$b8
000132793 7001_ $$aWeiderpass, Elisabete$$b9
000132793 7001_ $$aChirlaque, Maria-Dolores$$b10
000132793 7001_ $$aRodríguez-Barranco, Miguel$$b11
000132793 7001_ $$aAgudo, Antonio$$b12
000132793 7001_ $$aGunter, Marc$$b13
000132793 7001_ $$aDossus, Laure$$b14
000132793 7001_ $$aKrogh, Vittorio$$b15
000132793 7001_ $$aMatullo, Giuseppe$$b16
000132793 7001_ $$aTrichopoulou, Antonia$$b17
000132793 7001_ $$aTravis, Ruth C$$b18
000132793 7001_ $$0P:(DE-He78)5323704270b6393dcea70186ffd86bca$$aCanzian, Federico$$b19$$udkfz
000132793 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b20$$eLast author$$udkfz
000132793 773__ $$0PERI:(DE-600)2041618-0$$a10.1186/s13058-018-0955-5$$gVol. 20, no. 1, p. 29$$n1$$p29$$tBreast cancer research$$v20$$x1465-542X$$y2018
000132793 909CO $$ooai:inrepo02.dkfz.de:132793$$pVDB
000132793 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9c1a5b028ca0ab2ef3468a9266f81f63$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132793 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5323704270b6393dcea70186ffd86bca$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000132793 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000132793 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132793 9141_ $$y2018
000132793 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132793 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132793 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132793 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000132793 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000132793 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000132793 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBREAST CANCER RES : 2015
000132793 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132793 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132793 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132793 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132793 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132793 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBREAST CANCER RES : 2015
000132793 9201_ $$0I:(DE-He78)C055-20160331$$kC055$$lGenomische Epidemiologie$$x0
000132793 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x1
000132793 980__ $$ajournal
000132793 980__ $$aVDB
000132793 980__ $$aI:(DE-He78)C055-20160331
000132793 980__ $$aI:(DE-He78)C020-20160331
000132793 980__ $$aUNRESTRICTED